Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 34216146.
- Also identified by DOI 10.1002/lary.29730 and PMC identifier 9292739.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Eosinophilic otitis media (EOM) is a difficult-to-treat otitis media (OM) characterized by eosinophilic accumulation in the middle ear mucosa and secretion. Associated sensorineural hearing loss can eventually lead to (functional) deafness. EOM is strongly associated with type 2 inflammation driven respiratory disease, i.e. asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), for which biological treatment is available. This case report discusses a patient suffering from EOM with severe mixed hearing loss, nearing functional deafness. Dupilumab treatment resulted in complete and enduring remission of the EOM, enabling adequate hearing rehabilitation. Concurrent control of the comorbid asthma and CRSwNP was obtained. Laryngoscope, 131:2649-2651, 2021.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Eosinophilia
- Hearing Loss
- Otitis Media with Effusion